In this slidecast I will give the main reasons why you should invest in Omega Pharma. This is based on the Financial analysis of the first half of 2012.
3. Financial analysis
500
450
400
350
300
250 1H2012
200 1H2011
150
100
50
0
1 2 3 4
Key financial figures for the first half of 2012 Year on year evolution 1H2012 1H2011
Consolidated turnover +4% 471,2 454,4
Gross margin +6% 244,7 231,3
EBITDA +27% 82 64,7
Operating profit +35% 51 37,8
4. Consolidated income statement
Consolidated turnover Year on year evolution
Net Sales +4%
Cost of goods sold +1%
Gross Margin +6%
Operating Profit +35%
Finance income +9%
Finance cost +39%
Net Finance cost +40%
Result before income tax +33%
Income tax expense +38%
Result after income tax +32%
5. Capital injection
• ±5,2 million new shares
• 190 million EUR injected
Total assets (in EUR thousand) 1 969 363 1 495 707
Equity 850 362 633 215
Share capital and share premium 557 706 367 706
Retained earnings 417 437 388 475
Treasury shares -118 730 -118 730
Fair value and other reserves -5 572 -2 972
Cumulative translation adjustments -465 -1 261
Equity attributable to the shareholders of the parent 850 376 633 218
company
Equity attributable to non-controlling interests -14 -3
6. Innovation
New products/brands in the
following five categories:
• Derma
• Cough & Cold
• Parasites
• Classics
• Multi Locals
7. Conclusion
• New branches and products
• The net sales grew with 4%
• New shares in the company
• Joint venture with a South-African company